Tuesday, May 15, 2018

Ansun Biopharma Raises $85M

San Diego-based Ansun BioPharma, a biopharmaceuticals company which is focused on anti-virals for treating severe, viral respiratory tract infections, has raised $85M in a Series A funding. The funding was led by Sinopharm Healthcare Fund and Lilly Asia Ventures, and also included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, and Joincap Investment. As part of the funding, Sinopharm Capital's Dr. Xiaoming Yang, and Lilly Asia Ventures' Yi Shi join the board, as are Mr. Donald Payne and Dr. Michael Chao. Ansun said the new funding will go towards a Phase 3 clinical trial of its experimental anti-viral medication, DAS181. More information »